The company's core activity lies in the development and application of technologies for gene and cell therapy, particularly in the areas of Next-Generation Sequencing (NGS), genomic analysis platforms, cell lines, and vector production. The company offers solutions for the development and manufacturing of cell and gene therapies and focuses on providing platforms and services to the biopharmaceutical industry.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Next-generation sequencing, bioinformatics, sample preparation and technical support for cell line characterization, rAAV genome sequencing and customer-specific NGS services; uses Illumina, PacBio, Nanopore and Bionano.
Xcell™ Eng-HEK293 Cell Line
Proprietary HEK293 suspension cell line for transient rAAV production; available for licensing for laboratory and production environments, with high rAAV productivity, genomic stability and scalable production.
Xcell™ rAAV Production and Analytics Platform
Platform for production and testing of rAAV candidates; submit sequences, receive rAAV samples and a report, including titer and quality parameters as well as analytical support.
Xcell™ Eng-HEK293 Stable Manufacturing Platform
Stable producer cell lines for rAAV manufacturing; transition from transient to stable production with genomic stability, QA/QC, integration site analysis and scalable commercial manufacturing.
Gene therapy technologies
Technologies for the development and production of rAAV-based gene therapies; stable HEK cell lines with integrated genes for safe, scalable and reproducible vector production.
Knowledge
No knowledge articles yet
Once NewBiologix SA has claimed this profile, we'll publish editorial articles and case studies here together.